Metoclopramide Pediatric Dose — Gastrointestinal
Metoclopramide is a dopamine D2-receptor antagonist and prokinetic agent that enhances gastric emptying and accelerates gastrointestinal motility. It is used in pediatric patients for the management of gastroparesis, gastroesophageal reflux, and chemotherapy-induced or postoperative nausea and vomiting. Its central antiemetic action is mediated through antagonism of dopaminergic receptors in the chemoreceptor trigger zone.
Pediatric Dosing
- Dose: 0.1 mg/kg/dose IV or PO every 6 hours
- Maximum dose: 10 mg/dose
Administer no more than four doses per day (every 6 hours). The maximum single dose of 10 mg should not be exceeded regardless of weight.
Worked example: For a 20 kg child: 20 × 0.1 mg/kg = 2 mg per dose. For a 120 kg adolescent, cap at 10 mg per dose.
Indications and Clinical Context
Metoclopramide is indicated in pediatric patients for conditions requiring enhanced gastrointestinal motility, including gastroparesis, symptomatic gastroesophageal reflux disease (GERD), and nausea and vomiting associated with chemotherapy or postoperative states. It is classified as a prokinetic and antiemetic agent within the gastrointestinal pharmacotherapy category.
Use should be limited to the shortest effective duration given the risk of tardive dyskinesia with prolonged administration. Consult institutional protocol and current evidence-based guidelines when determining the appropriateness of metoclopramide therapy for individual patients, particularly in neonates and young infants, who may have heightened sensitivity to dopaminergic adverse effects.
Administration and Monitoring
Metoclopramide may be administered intravenously (IV) or orally (PO). When given IV, administer as a slow infusion over at least 15 minutes to minimize the risk of akathisia and extrapyramidal symptoms (EPS). Oral formulations should be given 30 minutes before meals when used for prokinetic indications.
- Max single dose: 10 mg regardless of weight
- Frequency: Every 6 hours (up to 4 doses/day)
- Monitor for: Extrapyramidal reactions (dystonia, akathisia), sedation, and neuroleptic malignant syndrome with prolonged use
- Contraindications: Known hypersensitivity, mechanical gastrointestinal obstruction, pheochromocytoma, and history of tardive dyskinesia
- Duration: Limit to the shortest effective course; consult institutional protocol for guidance on maximum treatment duration
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.